The obsolescence of sclerotherapy.
I read with great interest the recent practice guidance on development of quality measures in cirrhosis (1). I commend the authors for producing a set of measures which will enable healthcare professionals and service providers to evaluate quality of care and drive improvement. I am, however, somewhat concerned by the inclusion of sclerotherapy in their process measure 11, "patients with cirrhosis who are found to have bleeding esophageal varices should receive EVL or sclerotherapy at the time of index endoscopy" (1). This article is protected by copyright. All rights reserved.